In the long and uneven history of medicine's reach beyond its grasp, a six-year-old girl in China has become the quiet center of a gathering storm. Mei died approximately one week after receiving an experimental gene-editing infusion into her spinal fluid — a procedure her parents paid $800,000 to access — yet her death went unmentioned in the scientific literature that followed. Shanghai Jiao Tong University has now opened an investigation, confronting questions that extend far beyond one laboratory: who bears responsibility when ambition outruns accountability, and what is owed to the most v
Chinese University Probes Undisclosed Death in Gene-Editing Trial
A six-year-old girl died approximately one week after receiving an experimental spinal infusion of viruses for gene therapy targeting brain development.
A death wasn't disclosed in peer-reviewed literature
Mark
Why would a researcher publish findings about a therapy without mentioning that a patient died from it?
Mimi
The most charitable explanation is compartmentalization—the animal studies were separate from the human trial, so perhaps Qiu saw them as distinct projects. But that doesn't hold up. If you're publishing about a treatment you tested on humans, you have an obligation to disclose what happened to those humans.
Mark
Did the parents know what they were signing up for?
Mimi
Not fully, according to the investigation. They paid $800,000, which suggests they understood this was experimental and expensive. But "not adequately informed about the risks" means they didn't get the full picture of what could go wrong—or what did go wrong.
Mark
Is this just a Chinese problem?
Mimi
No. Research ethics violations happen everywhere. But China is still rebuilding trust after He Jiankui. When you're trying to prove you can do world-class science responsibly, you can't afford these kinds of lapses. One scandal is a scandal. Two starts to look like a pattern.
Mark
What happens now to Qiu?
Mimi
That depends on what the investigation finds. The university says it will take "serious action," but we don't know yet whether that means retracting the paper, suspending his research, or something more severe. The investigation itself will take time.
Mark
Could this have been prevented?
Mimi
Yes. Robust institutional review boards, independent oversight of human trials, mandatory reporting of adverse events—these exist for a reason. If they were in place and working, a death wouldn't have been buried in the first place.
Il Polso
- A six-year-old girl died roughly one week after receiving an experimental spinal infusion of engineered viruses meant to rewrite a gene affecting her brain development — a death that was never disclosed to the scientific community.
- The lead researcher published findings in Nature describing related animal studies without any mention of the child's death, raising immediate alarms about the integrity of the research record.
- Mei's parents paid over $800,000 to participate in the trial and were reportedly not given adequate information about the risks, pointing to a serious breakdown in informed consent.
- The story only surfaced through a joint investigation by Science magazine and Retraction Watch, underscoring how institutional silence can outlast individual tragedy.
- Shanghai Jiao Tong University has launched a formal investigation and warned of serious consequences, but the damage to China's biotech credibility — still raw from the 2018 He Jiankui scandal — may already be spreading.
In the long and uneven history of medicine's reach beyond its grasp, a six-year-old girl in China has become the quiet center of a gathering storm. Mei died approximately one week after receiving an experimental gene-editing infusion into her spinal fluid — a procedure her parents paid $800,000 to access — yet her death went unmentioned in the scientific literature that followed. Shanghai Jiao Tong University has now opened an investigation, confronting questions that extend far beyond one laboratory: who bears responsibility when ambition outruns accountability, and what is owed to the most vulnerable participants in the pursuit of medical progress?
Shanghai Jiao Tong University's School of Medicine announced Sunday that it had opened an investigation into the death of a six-year-old girl following an experimental gene-editing procedure — a death that the trial's lead researcher never disclosed in his published work.
The child, known only as Mei, received an infusion of trillions of engineered viruses directly into her spinal fluid about a year ago. The treatment was designed to cross the blood-brain barrier and correct a mutated gene responsible for a rare disorder that had severely impaired her cognitive development. She died approximately one week later. The fatality only became public through a joint investigation by Science magazine and Retraction Watch.
Lead researcher Zilong Qiu, a neuroscientist who had been working toward what would have been the world's first gene-editing therapy directly targeting the brain, subsequently published a paper in Nature on related animal studies. Mei's death was absent from it entirely — an omission that cast immediate doubt on the completeness of the therapy's reported safety profile.
Mei's parents had paid more than $800,000 to enroll in the trial and, according to investigators, were not adequately informed of the risks involved. The university acknowledged the gravity of the situation, stating its firm opposition to research conducted in violation of ethical norms and promising serious consequences upon the investigation's conclusion.
The case arrives at a deeply sensitive moment for Chinese science. The 2018 revelation that biophysicist He Jiankui had secretly created gene-edited babies drew global condemnation and raised lasting questions about oversight in Chinese research institutions. Mei's death — and the apparent effort to keep it from the scientific record — suggests those questions remain unanswered, and threatens to complicate China's broader ambitions to be taken seriously as a global leader in biotechnology.
Shanghai Jiao Tong University's School of Medicine announced on Sunday that it had launched an investigation into the death of a six-year-old girl who died following an experimental gene-editing treatment, a fatality that researchers had failed to disclose in their published work.
The child, identified only as Mei in reports, received an infusion of trillions of engineered viruses delivered directly into her spinal fluid roughly a year ago. The treatment was designed to cross the blood-brain barrier and rewrite a mutated gene responsible for a rare genetic disorder that had severely delayed her cognitive development. She died about a week after the procedure. The death came to light through a joint investigation by Science magazine and Retraction Watch, which published their findings on Thursday.
Zilong Qiu, a neuroscientist and the trial's lead researcher, subsequently published a paper in Nature describing related animal studies. The paper made no mention of Mei or her death. This omission raised immediate questions about research transparency and whether the scientific community had been given a complete picture of the therapy's safety profile. Qiu had been attempting to pioneer the world's first gene-editing treatment that directly targeted the brain—a significant undertaking in the field of genetic medicine.
Mei's parents had invested more than $800,000 to participate in the trial. According to the investigation, they were not adequately informed about the risks involved in the experimental procedure, raising concerns about informed consent and the ethical standards governing the research. The university's statement acknowledged these concerns, saying it "attaches great importance to scientific research integrity and research norms, and firmly opposes conducting medical scientific research in violation of scientific research ethics." Officials indicated that serious consequences would follow once the investigation concluded.
The incident arrives at a fraught moment for China's biotech sector. In 2018, biophysicist He Jiankui shocked the world by revealing he had secretly created gene-edited babies, an act that triggered international condemnation and damaged China's standing in the global scientific community. That scandal raised questions about oversight mechanisms and ethical guardrails in Chinese research institutions. The death of Mei, combined with the apparent failure to disclose it in peer-reviewed literature, suggests those concerns remain unresolved. As China seeks to establish itself as a biotech rival to the United States, incidents like this threaten to undermine the credibility and trustworthiness that such ambitions require.
Citazioni salienti
The School of Medicine has always attached great importance to scientific research integrity and research norms, and firmly opposes conducting medical scientific research in violation of scientific research ethics.— Shanghai Jiao Tong University School of Medicine statement
Vuoi la storia completa?
Leggi l'originale su VnExpress International ↗
Education